Neuphoria Therapeutics (NEUP) Other Non-Current Liabilities (2023 - 2026)

Neuphoria Therapeutics (NEUP) has reported Other Non-Current Liabilities for 4 consecutive years, with $2.5 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 30.2% year-over-year to $2.5 million in Q1 2026; TTM through Mar 2026 was $2.5 million, a 30.2% increase from a year earlier, with the FY2025 full-year figure at $3.7 million, down 20.53% from the prior year.
• Other Non-Current Liabilities was $2.5 million for Q1 2026 at Neuphoria Therapeutics, down from $2.7 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $8.1 million in Q3 2025 and troughed at $810125.0 in Q4 2024.
• A 4-year average of $3.2 million and a median of $2.5 million in 2026 frame the typical range for Other Non-Current Liabilities.
• The widest YoY moves for Other Non-Current Liabilities: up 378.38% in 2025, down 20.53% in 2025.
• Over 4 years, Other Non-Current Liabilities stood at $2.5 million in 2023, then sank by 67.02% to $810125.0 in 2024, then soared by 234.86% to $2.7 million in 2025, then slipped by 9.42% to $2.5 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $2.5 million (Q1 2026), $2.7 million (Q4 2025), and $8.1 million (Q3 2025), per Business Quant data.